2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenVideo: Novo Nordisk CEO: We were ahead of our time, and it cost us market shares. https://proinvestor.com/forum/topic/559969/video-novo-nordisk-topchef-vi-var-forud-for-vores-tid-og-det-kostede-os-markedsandele.
·3 t sittenElon Musk now backs Sam Altman, CEO of OpenAI, agreeing with Anthropic CEO Dario Amodei that the AI industry should slow down.!!! Can this cause a mass exodus away from tech on Monday towards medicine or is it just a dream?😅- ·5 t sittenIn the future, it may be possible to treat obesity in children between 6 and 12 years old with the weight loss medication Wegovy. At least, Novo Nordisk has presented the results from phase three of the 'Step Young' trial in a press release, where 165 overweight children between 6 and 12 years old participated. The majority of the children were classified as having severe obesity at the start of the trial. One half received treatment with semaglutide, also known under the name Wegovy and Ozempic, while the other half received placebo treatment. All children underwent lifestyle changes, such as reduced calorie intake and increased physical activity, during the 68 weeks the trial lasted. When the trial ended, 40.4 percent of the children who had received semaglutide could no longer be defined as "having obesity". The same applied to 0 percent of the children who received placebo
·6 t sitten · MuokattuAs soon as the slightest fly in the ointment is found regarding Novo Nordisk, fire chief Mr. Oracle Hansen Nordnet, comes out with his doomsday theories etc. But how many articles can you find about Coloplast - PURE DISASTER what's going on in that company - articles about Coloplast share price - articles about various financial institutions' announcements - articles that deal with comparison of previous years' prices - articles about future prospects NADER On the other hand, I am extremely pleased NOT to have listened to various know-it-alls and analysts in various Podcasts, without mentioning names but especially a certain podcast that rhymes with lige-ved-og nær klubben. So Nordnet, try to pull yourselves together - there are other shares than just Novo Nordisk you can start trashing and influencing shareholders
·10 t sitten · MuokattuHere are the AI expectations for the staff meeting on Tuesday (I have the paid version (pro)) : According to an employee invitation seen by Bloomberg, Novo Nordisk has summoned employees to a global town hall meeting on Tuesday, September 15. The wording in the invitation is that management will share an “exciting update about our company’s next chapter”. Novo has confirmed that the internal event is taking place. The interesting thing is that the meeting is only six days before Capital Markets Day on September 21. Novo itself describes CMD as a day where top management will review strategy, R&D pipeline, business, and performance. What do I think it's about? There is no public confirmation of the content itself yet, so I would be cautious about rumors of, for example, new layoffs. But the phrasing “exciting update” and “next chapter” makes me lean more towards a major strategic presentation than another ordinary cost-saving exercise. My preliminary probability estimate is approximately: Possibility My estimate 🟢 New strategic direction / organization / growth plan 45 % 🟢 Major pipeline or product strategy 25 % 🟡 Management/organizational changes 15 % 🔴 New major layoff/cost-saving plan 10 % 🟣 Something completely different, e.g., major transaction 5 % I especially think further massive layoffs seem less obvious. Novo already announced a transformation last year with approximately 9,000 positions eliminated and DKK 8 billion in annual savings. At Q2 2026, management also stated that they were ahead of schedule in realizing these savings. There are indeed employee rumors about another round of layoffs in September, but these are just rumors and not documentation. What I find most exciting I believe there might be a direct connection between: September 15 → employees are presented with “Novo's next chapter” September 21 → investors receive the financial and strategic explanation at Capital Markets Day. This actually fits very well with what we discussed regarding CMD: Novo needs to convince the market that 2025–26 was a transition period, and that Wegovy/oral Wegovy, CagriSema, amycretin/zenaiglutide and the rest of the pipeline can create a new growth period. I will therefore consider Tuesday's meeting as potentially price-sensitive. The wording in the invitation is unusually positive. This does not necessarily mean that a major stock exchange announcement will come on Tuesday, but I think the probability of getting a first hint of what Novo will present at CMD is quite high. And since you bought Novo around 276 kr., I actually think that the period September 15–21 could be one of the more interesting weeks for your Novo investment this year. I can keep an eye on new information and rumors leading up to Tuesday and let you know if anything credible emerges about what “next chapter” specifically means.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenVideo: Novo Nordisk CEO: We were ahead of our time, and it cost us market shares. https://proinvestor.com/forum/topic/559969/video-novo-nordisk-topchef-vi-var-forud-for-vores-tid-og-det-kostede-os-markedsandele.
- ·3 t sittenElon Musk now backs Sam Altman, CEO of OpenAI, agreeing with Anthropic CEO Dario Amodei that the AI industry should slow down.!!! Can this cause a mass exodus away from tech on Monday towards medicine or is it just a dream?😅
- ·5 t sittenIn the future, it may be possible to treat obesity in children between 6 and 12 years old with the weight loss medication Wegovy. At least, Novo Nordisk has presented the results from phase three of the 'Step Young' trial in a press release, where 165 overweight children between 6 and 12 years old participated. The majority of the children were classified as having severe obesity at the start of the trial. One half received treatment with semaglutide, also known under the name Wegovy and Ozempic, while the other half received placebo treatment. All children underwent lifestyle changes, such as reduced calorie intake and increased physical activity, during the 68 weeks the trial lasted. When the trial ended, 40.4 percent of the children who had received semaglutide could no longer be defined as "having obesity". The same applied to 0 percent of the children who received placebo
- ·6 t sitten · MuokattuAs soon as the slightest fly in the ointment is found regarding Novo Nordisk, fire chief Mr. Oracle Hansen Nordnet, comes out with his doomsday theories etc. But how many articles can you find about Coloplast - PURE DISASTER what's going on in that company - articles about Coloplast share price - articles about various financial institutions' announcements - articles that deal with comparison of previous years' prices - articles about future prospects NADER On the other hand, I am extremely pleased NOT to have listened to various know-it-alls and analysts in various Podcasts, without mentioning names but especially a certain podcast that rhymes with lige-ved-og nær klubben. So Nordnet, try to pull yourselves together - there are other shares than just Novo Nordisk you can start trashing and influencing shareholders
- ·10 t sitten · MuokattuHere are the AI expectations for the staff meeting on Tuesday (I have the paid version (pro)) : According to an employee invitation seen by Bloomberg, Novo Nordisk has summoned employees to a global town hall meeting on Tuesday, September 15. The wording in the invitation is that management will share an “exciting update about our company’s next chapter”. Novo has confirmed that the internal event is taking place. The interesting thing is that the meeting is only six days before Capital Markets Day on September 21. Novo itself describes CMD as a day where top management will review strategy, R&D pipeline, business, and performance. What do I think it's about? There is no public confirmation of the content itself yet, so I would be cautious about rumors of, for example, new layoffs. But the phrasing “exciting update” and “next chapter” makes me lean more towards a major strategic presentation than another ordinary cost-saving exercise. My preliminary probability estimate is approximately: Possibility My estimate 🟢 New strategic direction / organization / growth plan 45 % 🟢 Major pipeline or product strategy 25 % 🟡 Management/organizational changes 15 % 🔴 New major layoff/cost-saving plan 10 % 🟣 Something completely different, e.g., major transaction 5 % I especially think further massive layoffs seem less obvious. Novo already announced a transformation last year with approximately 9,000 positions eliminated and DKK 8 billion in annual savings. At Q2 2026, management also stated that they were ahead of schedule in realizing these savings. There are indeed employee rumors about another round of layoffs in September, but these are just rumors and not documentation. What I find most exciting I believe there might be a direct connection between: September 15 → employees are presented with “Novo's next chapter” September 21 → investors receive the financial and strategic explanation at Capital Markets Day. This actually fits very well with what we discussed regarding CMD: Novo needs to convince the market that 2025–26 was a transition period, and that Wegovy/oral Wegovy, CagriSema, amycretin/zenaiglutide and the rest of the pipeline can create a new growth period. I will therefore consider Tuesday's meeting as potentially price-sensitive. The wording in the invitation is unusually positive. This does not necessarily mean that a major stock exchange announcement will come on Tuesday, but I think the probability of getting a first hint of what Novo will present at CMD is quite high. And since you bought Novo around 276 kr., I actually think that the period September 15–21 could be one of the more interesting weeks for your Novo investment this year. I can keep an eye on new information and rumors leading up to Tuesday and let you know if anything credible emerges about what “next chapter” specifically means.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenVideo: Novo Nordisk CEO: We were ahead of our time, and it cost us market shares. https://proinvestor.com/forum/topic/559969/video-novo-nordisk-topchef-vi-var-forud-for-vores-tid-og-det-kostede-os-markedsandele.
- ·3 t sittenElon Musk now backs Sam Altman, CEO of OpenAI, agreeing with Anthropic CEO Dario Amodei that the AI industry should slow down.!!! Can this cause a mass exodus away from tech on Monday towards medicine or is it just a dream?😅
- ·5 t sittenIn the future, it may be possible to treat obesity in children between 6 and 12 years old with the weight loss medication Wegovy. At least, Novo Nordisk has presented the results from phase three of the 'Step Young' trial in a press release, where 165 overweight children between 6 and 12 years old participated. The majority of the children were classified as having severe obesity at the start of the trial. One half received treatment with semaglutide, also known under the name Wegovy and Ozempic, while the other half received placebo treatment. All children underwent lifestyle changes, such as reduced calorie intake and increased physical activity, during the 68 weeks the trial lasted. When the trial ended, 40.4 percent of the children who had received semaglutide could no longer be defined as "having obesity". The same applied to 0 percent of the children who received placebo
- ·6 t sitten · MuokattuAs soon as the slightest fly in the ointment is found regarding Novo Nordisk, fire chief Mr. Oracle Hansen Nordnet, comes out with his doomsday theories etc. But how many articles can you find about Coloplast - PURE DISASTER what's going on in that company - articles about Coloplast share price - articles about various financial institutions' announcements - articles that deal with comparison of previous years' prices - articles about future prospects NADER On the other hand, I am extremely pleased NOT to have listened to various know-it-alls and analysts in various Podcasts, without mentioning names but especially a certain podcast that rhymes with lige-ved-og nær klubben. So Nordnet, try to pull yourselves together - there are other shares than just Novo Nordisk you can start trashing and influencing shareholders
- ·10 t sitten · MuokattuHere are the AI expectations for the staff meeting on Tuesday (I have the paid version (pro)) : According to an employee invitation seen by Bloomberg, Novo Nordisk has summoned employees to a global town hall meeting on Tuesday, September 15. The wording in the invitation is that management will share an “exciting update about our company’s next chapter”. Novo has confirmed that the internal event is taking place. The interesting thing is that the meeting is only six days before Capital Markets Day on September 21. Novo itself describes CMD as a day where top management will review strategy, R&D pipeline, business, and performance. What do I think it's about? There is no public confirmation of the content itself yet, so I would be cautious about rumors of, for example, new layoffs. But the phrasing “exciting update” and “next chapter” makes me lean more towards a major strategic presentation than another ordinary cost-saving exercise. My preliminary probability estimate is approximately: Possibility My estimate 🟢 New strategic direction / organization / growth plan 45 % 🟢 Major pipeline or product strategy 25 % 🟡 Management/organizational changes 15 % 🔴 New major layoff/cost-saving plan 10 % 🟣 Something completely different, e.g., major transaction 5 % I especially think further massive layoffs seem less obvious. Novo already announced a transformation last year with approximately 9,000 positions eliminated and DKK 8 billion in annual savings. At Q2 2026, management also stated that they were ahead of schedule in realizing these savings. There are indeed employee rumors about another round of layoffs in September, but these are just rumors and not documentation. What I find most exciting I believe there might be a direct connection between: September 15 → employees are presented with “Novo's next chapter” September 21 → investors receive the financial and strategic explanation at Capital Markets Day. This actually fits very well with what we discussed regarding CMD: Novo needs to convince the market that 2025–26 was a transition period, and that Wegovy/oral Wegovy, CagriSema, amycretin/zenaiglutide and the rest of the pipeline can create a new growth period. I will therefore consider Tuesday's meeting as potentially price-sensitive. The wording in the invitation is unusually positive. This does not necessarily mean that a major stock exchange announcement will come on Tuesday, but I think the probability of getting a first hint of what Novo will present at CMD is quite high. And since you bought Novo around 276 kr., I actually think that the period September 15–21 could be one of the more interesting weeks for your Novo investment this year. I can keep an eye on new information and rumors leading up to Tuesday and let you know if anything credible emerges about what “next chapter” specifically means.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt